Last reviewed · How we verify
Colistin and saline solution
Colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides, causing cell lysis and death in gram-negative bacteria.
Colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides, causing cell lysis and death in gram-negative bacteria. Used for Respiratory tract infections caused by multidrug-resistant gram-negative bacteria (Pseudomonas aeruginosa, Acinetobacter baumannii), Ventilator-associated pneumonia in hospitalized patients.
At a glance
| Generic name | Colistin and saline solution |
|---|---|
| Sponsor | Hospitales Universitarios Virgen del Rocío |
| Drug class | Polymyxin antibiotic |
| Target | Bacterial lipopolysaccharide (LPS) and cell membrane |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Colistin acts as a cationic antimicrobial peptide that interacts with the outer membrane of gram-negative bacteria, particularly effective against multidrug-resistant organisms like Pseudomonas aeruginosa and Acinetobacter baumannii. The saline solution serves as a vehicle for delivery and maintains osmotic balance. This combination is typically used for inhalation therapy to treat respiratory infections in hospitalized patients.
Approved indications
- Respiratory tract infections caused by multidrug-resistant gram-negative bacteria (Pseudomonas aeruginosa, Acinetobacter baumannii)
- Ventilator-associated pneumonia in hospitalized patients
Common side effects
- Nephrotoxicity
- Neurotoxicity (paresthesia, dizziness)
- Bronchospasm
- Respiratory tract irritation
Key clinical trials
- Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2, PHASE3)
- Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial (NA)
- Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline (PHASE4)
- Inhaled Polymyxin E to Prevent VAP (NA)
- Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium. (PHASE3)
- Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I) (PHASE3)
- Efficacy and Safety of Colistin Based Antibiotic Therapy (PHASE1, PHASE2)
- Colistin-rifampin Combination and Colistin Monotherapy in Extensively Drug-resistant Acinetobacter Baumannii (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |